0001104659-22-008048.txt : 20220127 0001104659-22-008048.hdr.sgml : 20220127 20220127080136 ACCESSION NUMBER: 0001104659-22-008048 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220125 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220127 DATE AS OF CHANGE: 20220127 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biostage, Inc. CENTRAL INDEX KEY: 0001563665 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 455210462 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35853 FILM NUMBER: 22559922 BUSINESS ADDRESS: STREET 1: 84 OCTOBER HILL ROAD STREET 2: SUITE 11 CITY: HOLLISTON STATE: MA ZIP: 01746 BUSINESS PHONE: (774) 233-7300 MAIL ADDRESS: STREET 1: 84 OCTOBER HILL ROAD STREET 2: SUITE 11 CITY: HOLLISTON STATE: MA ZIP: 01746 FORMER COMPANY: FORMER CONFORMED NAME: Harvard Apparatus Regenerative Technology, Inc. DATE OF NAME CHANGE: 20121204 8-K 1 tm224636d1_8k.htm FORM 8-K
0001563665 false 0001563665 2022-01-25 2022-01-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 25, 2022

 

BIOSTAGE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-35853 45-5210462

(State or other jurisdiction

of incorporation)

 (Commission File Number) (IRS Employer Identification No.)

 

84 October Hill Road, Suite 11, Holliston, MA 01746
(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code: (774) 233-7300

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
N/A N/A N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 8.01 Other Events.

 

Litigation Update

 

On January 25, 2022, Biostage, Inc. (the “Company”, “we,” “our,” and “us”) issued a press release announcing that the Court hearing the Company’s dispute with its product liability insurance carrier as to the defense of a wrongful death complaint that was filed against the Company and other defendants in 2017. As further described in the release, the Court issued a Preliminary Injunction Order requiring such carrier to continue paying for the defense of the underlying litigation. Although the coverage dispute remains pending between the parties and there can be no assurance that we will ultimately prevail in such coverage litigation, the Court held that the insurance carrier will mostly likely lose its claim seeking to terminate the payment of the defense, and therefore, it must continue to pay the defense until the coverage dispute is resolved. The Court also awarded the Company its attorneys’ fees and costs arising from the carrier’s breach of the duty to defend. The Company will continue to vigorously defend against carrier’s denial of coverage and related matters, as well as continue to vigorously defend against the claims in the underlying case.

 

The full text of the press release is attached as Exhibit 99.1 hereto and incorporated by reference into this Item 8.01.

 

Webinar

 

On January 25, 2022, the Company also issued a press release announcing that it will be hosting two webinars to allow investors to meet its new Interim CEO, David Green. During the webinars Mr. Green will review the Company’s plans for its approved clinical trial, raising capital and uplisting to NASDAQ.

 

The full text of the press release, including a link to register for the webinars, is attached as Exhibit 99.2 hereto and incorporated by reference into this Item 8.01.

 

Forward-Looking Statements 

 

This Current Report on Form 8-k includes statements that are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include, but are not limited to, statements relating to the litigation matters described above, our defense of such matters and the impact of such matters, including on our financial condition and operations. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this Form 8-k, including, among other things, factors described under the heading "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 or described in the Company's other public filings. The forward-looking statements in this Form 8-k speak only as of the date of this Form 8-k. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number		  Title
99.1  Press Release issued by Biostage, Inc. on January 25, 2022
99.2  Press Release issued by Biostage, Inc. on January 25, 2022

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      BIOSTAGE, INC.
      (Registrant)
       
January 27, 2022     /s/ David Green
(Date)     David Green
      Interim Chief Executive Officer

 

3

 EX-99.1 2 tm224636d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Biostage Announces Court’s Preliminary Injunction Order Requiring its Insurance Carrier to Continue Paying for Defense.

 

Court holds that Biostage’s insurer breached its duty to defend a litigation from the estate of a patient who died after being treated with a Biostage Tracheal Implant.

 

HOLLISTON, Mass., Jan. 25th, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today announced that a Court has ordered that its medical liability insurance carrier, Medmarc, breached its duty to defend the Company when Medmarc unilaterally stopped paying Biostage’s legal bills for the defense in the litigation from the estate of a patient who died after being treated with a Biostage Tracheal Implant. In September 2021, Medmarc filed a lawsuit seeking to be relieved of its duty to defend and indemnify Biostage in the litigation. At that time, Medmarc stopped paying the Company’s defense costs in the litigation. Biostage responded by filing claims against Medmarc for insurance coverage, and Biostage also brought a motion seeking the Court to Order Medmarc to continue paying for the Company’s reasonable defense costs in the underlying litigation while the coverage dispute is pending.

 

The Court granted Biostage’s motion for preliminary injunction and held that Medmarc breached its duty to defend the Company when it unilaterally stopped paying for the defense. The Court expressly stated that Medmarc engaged in “unlawful conduct” by unilaterally terminating the defense. Although the coverage dispute remains pending between the parties, the Court held that “Medmarc will mostly likely lose its claim” seeking to terminate the payment of the defense, and therefore, it must continue to pay the defense until the coverage dispute is resolved.

 

The Court also awarded Biostage its attorneys’ fees and costs arising from Medmarc’s breach of the duty to defend. The Court’s decision states that “when an insured goes to court and shows that the insurer has breached its duty to defend, the insured is entitled to recovery any reasonable attorneys’ fees and other litigation expenses that it incurred to do so.”

 

Biostage has since discontinued development of the Biostage Tracheal Implant and is now pursuing the development of the Biostage Esophageal Implant to treat adults with severe esophageal disease (including esophageal cancer), and also birth defects in the esophagus in babies.

 

 

 

 

Chairman and Interim CEO of Biostage, David Green, commented, “We are very pleased that a Court of law has ordered Medmarc to continue to pay to defend us in this litigation. This preliminary order will reduce Biostage’s cash outflows and will protect investors in Biostage by reinstating the defense in the underlying case.”

 

About Biostage.

 

Biostage is a clinical-stage biotech company that uses cell therapy to regenerate organs inside the human body to treat cancer, trauma and birth defects. We have performed the world's first regeneration of an esophagus in a human cancer patient. This surgery was performed at Mayo Clinic and was published in August 2021. 

 

The Biostage Esophageal Implant is not a transplant of someone else’s organ. It is not a transplant of an organ grown in a pig. It is not a piece of your bowel in your chest. It is not a piece of plastic left permanently in your esophagus. The Biostage Esophageal Implant uses your own stem cells to regenerate your own organ, inside your own body. Once the regeneration is complete, and a new esophagus has formed, typically in 2-3 months, the plastic scaffold is removed via the mouth.

 

Biostage has 7 issued U.S. patents, 2 orphan-drug designations (which provide 7 years of market exclusivity in addition to any patents), and the possibility of 2 Priority Review Vouchers from the FDA. 

 

Biostage's current goals include raising capital, uplisting from the OTC bulletin board to NASDAQ and beginning its clinical trial for repair of the esophagus in adults. 

 

Forward-Looking Statements 

 

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to the capabilities and performance of our products and product candidates; our capital raising plans and expectations, including uplifting to NASDAQ; development expectations and regulatory approval of any of the Company's products, including those utilizing its Biostage Esophageal Implant technology, by the U.S. Food and Drug Administration, the European Medicines Agency or otherwise, which expectations or approvals may not be achieved or obtained on a timely basis or at all; and success with respect to any collaborations, clinical trials and other development and commercialization efforts of the Company's products, which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the Company's inability to obtain needed funds in the immediate future; the Company's ability to obtain and maintain regulatory approval for its products; plus other factors described under the heading "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 or described in the Company's other public filings. The Company's results may also be affected by factors of which the Company is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

 

Investor Relations Contact
Shunfu Hu
Vice President of Business Development
and Operations
774-233-7300
shu@biostage.com

 

 

 EX-99.2 3 tm224636d1_ex99-2.htm EXHIBIT 99.2

 

Exhibit 99.2

 

Biostage Announces “Meet the Founder, New Chairman and Interim CEO” Webinar

Thursday, Jan. 27. 2-3pm ET via Zoom

Thursday, Jan. 27. 8-9pm ET / 9-10am Friday, January 28 Beijing Time via Zoom

 

HOLLISTON, Mass., Jan. 25th, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today announced that it will be hosting a webinar to allow investors to meet its new Interim CEO, David Green. Mr. Green is also Biostage’s founder and is the Chairman of its Board of Directors. Mr. Green will review Biostage’s plans for its approved clinical trial, raising capital and uplisting to NASDAQ. There will be an opportunity for Q&A.

 

The Biostage Esophageal Implant is not a transplant of someone else’s organ. It is not a transplant of an organ grown in a pig. It is not a piece of your bowel in your chest. It is not a piece of plastic left permanently in your esophagus. The Biostage Esophageal Implant uses your own stem cells to regenerate your own organ, inside your own body. Once the regeneration is complete, and a new esophagus has formed, typically in 2-3 months, the plastic scaffold is removed via the mouth.

 

The webinar will be held this Thursday, January 27, 2022, at 2pm ET via Zoom. There will be time for investors to ask questions directly to Mr. Green. The webinar will be repeated Thursday, Jan. 27. 8-9pm ET / 9-10am Friday, January 28 Beijing Time via Zoom.

 

Click here to register for the Thursday 2pm ET webinar:

https://us02web.zoom.us/webinar/register/WN_5Ig4one3QBO7NGiWZnyl1A

 

Click here to register for the Friday 9am Beijing Time (Thursday 8pm ET) webinar:

https://us02web.zoom.us/webinar/register/WN_0S1wpteyQHOlmwm6Me4RTA

 

This webinar and accompanying survey do not constitute an offer, or invitation, or solicitation of an offer, to subscribe for or purchase any securities.  Neither this presentation, nor this survey nor anything contained therein or herein shall form the basis of any contract or commitment whatsoever.

 

 

 

 

About Biostage.

 

Biostage is a clinical-stage biotech company that uses cell therapy to regenerate organs inside the human body to treat cancer, trauma and birth defects. We have performed the world's first regeneration of an esophagus in a human cancer patient. This surgery was performed at Mayo Clinic and was published in August 2021. 

 

Biostage has 7 issued U.S. patents, 2 orphan-drug designations (which provide 7 years of market exclusivity in addition to any patents), and the possibility of 2 Priority Review Vouchers from the FDA. 

 

Biostage's current goals include raising capital, uplisting from the OTC bulletin board to NASDAQ and beginning its clinical trial for repair of the esophagus in adults. 

 

Forward-Looking Statements 

 

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to the capabilities and performance of our products and product candidates; our capital raising plans and expectations, including uplifting to NASDAQ; development expectations and regulatory approval of any of the Company's products, including those utilizing its Biostage Esophageal Implant technology, by the U.S. Food and Drug Administration, the European Medicines Agency or otherwise, which expectations or approvals may not be achieved or obtained on a timely basis or at all; and success with respect to any collaborations, clinical trials and other development and commercialization efforts of the Company's products, which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the Company's inability to obtain needed funds in the immediate future; the Company's ability to obtain and maintain regulatory approval for its products; plus other factors described under the heading "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 or described in the Company's other public filings. The Company's results may also be affected by factors of which the Company is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

 

Investor Relations Contact
Shunfu Hu
Vice President of Business Development
and Operations
774-233-7300
shu@biostage.com

 

 

 EX-101.SCH 4 bstg-20220125.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 bstg-20220125_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 bstg-20220125_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Jan. 25, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 25, 2022
Entity File Number 001-35853
Entity Registrant Name BIOSTAGE, INC.
Entity Central Index Key 0001563665
Entity Tax Identification Number 45-5210462
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 84 October Hill Road
Entity Address, Address Line Two Suite 11
Entity Address, City or Town Holliston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01746
City Area Code 774
Local Phone Number 233-7300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
XML 8 tm224636d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001563665 2022-01-25 2022-01-25 iso4217:USD shares iso4217:USD shares 0001563665 false 8-K 2022-01-25 BIOSTAGE, INC. DE 001-35853 45-5210462 84 October Hill Road Suite 11 Holliston MA 01746 774 233-7300 false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 122 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://biostage.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm224636d1_8k.htm bstg-20220125.xsd bstg-20220125_lab.xml bstg-20220125_pre.xml tm224636d1_ex99-1.htm tm224636d1_ex99-2.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm224636d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm224636d1_8k.htm" ] }, "labelLink": { "local": [ "bstg-20220125_lab.xml" ] }, "presentationLink": { "local": [ "bstg-20220125_pre.xml" ] }, "schema": { "local": [ "bstg-20220125.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bstg", "nsuri": "http://biostage.com/20220125", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm224636d1_8k.htm", "contextRef": "From2022-01-25to2022-01-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://biostage.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm224636d1_8k.htm", "contextRef": "From2022-01-25to2022-01-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biostage.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-008048-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-008048-xbrl.zip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�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end